Pfizer Inc. (PFE) is a multinational pharmaceutical and biotechnology company. The company researches, develops and manufactures biopharmaceutical products in many different fields, including oncology, cardiovascular diseases, inflammatory diseases, immunology, rare diseases and vaccines. Pfizer collaborated with BioNTech SE (BNTX), a biotechnology company based in Germany, to develop an mRNA-based COVID-19 vaccine. The Pfizer-BioNTech vaccine has been used in millions of people in the United States and abroad, and sales may increase further as the United States and other countries carry out enhanced injections to further protect people from viral infections.
Pfizer’s largest shareholders are Frank A. D’amelio, John Douglas Young, Mikael Dolsten, Vanguard Group Inc., BlackRock Inc. (BLK) and State Street Corp. (STT).
On August 23, 2021, the U.S. Food and Drug Administration (FDA) approved the Pfizer-BioNTech COVID-19 vaccine, which is now sold under the name Comirnaty. Previously, the vaccine was only approved under an emergency use authorization (EUA). It became the first vaccine against COVID-19 to be fully approved by the FDA. The vaccine continues to be available under the EUA, including individuals between 12 and 15 years of age.
Pfizer’s net income and revenue in the past 12 months were 13.2 billion U.S. dollars and 51.6 billion U.S. dollars, respectively. The company’s market value is approximately 248.4 billion U.S. dollars. These financial data are as of September 16, 2021.
“Internal personnel” refers to persons who hold senior management positions, members of the board of directors, and persons or entities that hold more than 10% of the company’s shares. In this case, it has nothing to do with insider trading.
Top 3 individual internal shareholders
The shares owned by individual internal shareholders are shares held through direct ownership. The shares mentioned in this section do not include indirectly held shares or shares acquired through stock options. Every time a company insider buys or sells a company’s stock that is deemed significant, it must file an SEC Form 4.
Frank A. Damerio
Frank A. D’amelio owns a total of 483,188 Pfizer shares, representing 0.01% of the company’s total issued shares. D’amelio is the Chief Financial Officer (CFO) and Executive Vice President of Global Supply. He is responsible for overseeing the company’s corporate financial functions, including auditing, finance, taxation, insurance, commercial finance and analysis. D’amelio is responsible for leading Pfizer’s acquisitions of Wyeth Pharmaceuticals, King Pharmaceuticals, Hospira Inc., Anacor Pharmaceuticals Inc. and Medivation Inc. He also led the spin-off of Zoetis, the company’s animal health business, and the sale of its nutrition business. Prior to joining Pfizer in 2007, D’amelio served as Chief Administrative Officer and Senior Executive Vice President of Integration at Alcatel-Lucent.
John Douglas Young
John Douglas Young owns a total of 461,761 Pfizer shares, representing 0.01% of the company’s total issued shares. Young has been with Pfizer for more than 30 years and is the company’s group president and chief commercial officer. Prior to his current position, he was the president of Pfizer’s Innovative Health Group, which includes six independent business units, focusing on the development of innovative drugs and vaccines. Young is also responsible for expanding Pfizer’s footprint in emerging markets in Latin America, Asia, Africa and the Middle East. Before that, he was the group president of Pfizer Essential Health. Young also serves as a member of the board of directors of a consumer healthcare company in a joint venture with GlaxoSmithKline (GSK) and a member of the board of directors of Johnson Controls International (JCI).
Mikael Dolsten owns a total of 137,727 shares of Pfizer, accounting for less than 0.01% of the company’s total outstanding shares. Dolsten is the Chief Scientific Officer and President of Global Research, Development and Medical (WRDM) at Pfizer. His focus is on scientific breakthroughs in small molecule drugs, biological therapies, gene therapies and vaccines. As the president of WRDM, Dolsten is responsible for overseeing all research departments of Pfizer, including oncology, internal medicine, inflammation and immunology, vaccines, rare diseases and therapeutic innovation centers. Prior to joining Pfizer in 2009, he served as President of Wyeth Research. Prior to that, he served as Executive Vice President and Head of Global Research at Boehringer Ingelheim. Dolsten is the inventor of multiple patents and has published approximately 150 articles in international journals.
Top three institutional shareholders
Institutional investors hold 65-66% of Pfizer’s total issued shares.
According to the company’s 13F document as of June 30, 2021, Pioneer Group owns 456.2 million shares of Pfizer, accounting for 8.1% of the total issued shares. The company is primarily a mutual fund and ETF management company, managing approximately US$7.2 trillion in global assets (AUM). Vanguard S&P 500 ETF (VOO) is one of the company’s largest exchange-traded funds (ETF), with an asset management scale of approximately US$256 billion. Pfizer accounts for nearly 0.7% of VOO’s holdings.
According to the company’s 13F document as of June 30, 2021, BlackRock owns 407 million Pfizer shares, representing 7.3% of the total issued shares. The company is mainly a mutual fund and ETF management company with assets under management of approximately US$8.7 trillion. The iShares Core S&P 500 ETF (IVV) is one of BlackRock’s largest ETFs, with an asset under management of approximately US$305 billion. Pfizer accounts for nearly 0.7% of IVV’s holdings.
State Street Bank
According to Pfizer’s 13F document as of June 30, 2021, State Street owns 278.6 million Pfizer shares, representing 5.0% of the total issued shares. The company mainly manages mutual funds, ETFs and other assets, with an asset management scale of approximately US$3.9 trillion. SPDR S&P 500 ETF Trust (SPY) is one of State Street’s largest ETFs, with an asset management scale of approximately US$410 billion. Pfizer accounts for nearly 0.7% of SPY’s holdings.